Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLYNN: Lidocaine 5% Patch for Prevention of Neuropathic Pain After Osteoporotic Vertebral Fracture
2025-524889-25-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lidocaine in osteoporotic vertebral fracture (OVF) and Neuralgia (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Onset of neuropathic pain at 2 months. Planned start Jul 2026; status: authorised.
02
Drugs
lidocaine
03
Conditions
osteoporotic vertebral fracture (OVF)Neuralgia
Beyond the preview
Go deeper on 2025-524889-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524889-25-00.